comparemela.com

Page 8 - World Dynamix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Primary Care Providers Report a High Unmet Need for New Therapeutic Treatment Options for Chronic Kidney Disease, Despite Earlier Intervention and Referrals to Nephrologists, Spherix Reports

/PRNewswire/ Approximately 37 million Americans have chronic kidney disease (CKD) that is one out of every seven U.S. adults.1 Many of these patients are.

New Research from Spherix Finds Increased Use of SGLT2 Inhibitors Across the EU5, Including AstraZeneca s Forxiga (Farxiga in US), in the Management of IgA Nephropathy Patients

European Nephrologists Lead the Way with Adoption of Astellas/FibroGen s HIF-PH inhibitor, EVRENZO (roxadustat), for Anemia of CKD Treatment in Both Dialysis and Non-Dialysis Settings, Spherix Report Finds

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.